118. Rollins BJ, Chemokines. Blood 1997;90(3):909–928.

119. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol

1994;6(6):865–873.

120. Hebert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleukin-8 identifies a cluster of

residues required for receptor binding. J Biol Chem 1991;266(28):18989–18994.

121. Clark-Lewis I, Dewald B, Geiser T, et al. Platelet factor 4 binds to interleukin 8 receptors and

activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci U S A

1993;90(8):3574–3577.

122. Clark-Lewis I, Kim KS, Rajarathnam K, et al. Structure-activity relationships of chemokines. J

Leukoc Biol 1995;57(5):703–711.

123. D’Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor

(interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992;176(5):1387–1398.

124. Shu U, Kiniwa M, Wu CY, et al. Activated T cells induce interleukin-12 production by monocytes

via CD40-CD40 ligand interaction. Eur J Immunol 1995;25(4):1125–1128.

125. Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares

identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase

protein response in liver cells. Proc Natl Acad Sci U S A 1987;84(20):7251–7255.

126. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253–278.

127. LeMay LG, Otterness IG, Vander AJ, et al. In vivo evidence that the rise in plasma IL 6 following

injection of a fever-inducing dose of LPS is mediated by IL 1 beta. Cytokine 1990;2(3):199–204.

128. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction

of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood

1994;83(1):113–118.

129. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility

group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med

2005;33(3):564–573.

130. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to

redirect it towards secretion. EMBO J 2003;22(20):5551–5560.

131. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers

227

http://surgerybook.net/

inflammation. Nature 2002;418(6894):191–195.

132. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a

non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3(10):995–1001.

133. Tang D, Shi Y, Kang R, et al. Hydrogen peroxide stimulates macrophages and monocytes to actively

release HMGB1. J Leukoc Biol 2007;81(3):741–747.

134. Zhang X, Wheeler D, Tang Y, et al. Calcium/calmodulin-dependent protein kinase (CaMK) IV

mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation

of macrophages. J Immunol 2008;181(7):5015–5023.

135. Chen G, Li J, Ochani M, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly

through CD14- and TNF-dependent mechanisms. J Leukoc Biol 2004;76(5):994–1001.

136. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human

microvascular endothelial cells. Blood 2003;101(7):2652–2660.

137. Rouhiainen A, Tumova S, Valmu L, et al. Pivotal advance: analysis of proinflammatory activity of

highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007;81(1):49–58.

138. Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis 2003;35(9):577–584.

139. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates

proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192(4):565–570.

140. Andersson UG, Tracey KJ. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J

Intern Med 2004;255(3):318–319.

141. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med

2003;9(5):517–524.

142. Sama AE, D’Amore J, Ward MF, et al. Bench to bedside: HMGB1-a novel proinflammatory cytokine

and potential therapeutic target for septic patients in the emergency department. Acad Emerg Med

2004;11(8):867–873.

143. Erlandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory

mediator. Eur J Immunol 2004;34(6):1503–1512.

144. Rovere-Querini P. Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant

released by necrotic cells. EMBO Rep 2004;5(8):825–830.

145. Peltz ED, Moore EE, Eckels PC, et al. Hmgb1 is markedly elevated within 6 hours of mechanical

trauma in humans. Shock 2009;32(1):17–22.

146. Ombrellino M, Wang H, Ajemian MS, et al. Increased serum concentrations of high-mobility-group

protein 1 in haemorrhagic shock. Lancet 1999;354(9188):1446–1447.

147. Jiang W, Pisetsky DS. Mechanisms of Disease: the role of high-mobility group protein 1 in the

pathogenesis of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3(1):52–58.

148. Rifkin IR, Leadbetter EA, Busconi L, et al. Toll-like receptors, endogenous ligands, and systemic

autoimmune disease. Immunol Rev 2005;204:27–42.

149. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis.

Nat Clin Pract Rheumatol 2007;3(7):382–390.

150. Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a

role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum

2003;48(4):971–981.

151. Bogdan C. The function of type I interferons in antimicrobial immunity. Curr Opin Immunol

2000;12(4):419–424.

152. De Maeyer E, De Maeyer-Guignard J. Type I interferons. Int Rev Immunol 1998;17(1–4):53–73.

153. Uze G, Lutfalla G, Mogensen KE. Alpha and beta interferons and their receptor and their friends

and relations. J Interferon Cytokine Res 1995;15(1):3–26.

154. Selzman CH, Shames BD, Miller SA, et al. Therapeutic implications of interleukin-10 in surgical

disease. Shock 1998;10(5):309–318.

155. Cassatella MA, Meda L, Bonora S, et al. Interleukin 10 (IL-10) inhibits the release of

proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine

role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by

lipopolysaccharide. J Exp Med 1993;178(6):2207–2211.

156. Neurath MF, Meyer zum Buschenfelde KH. Protective and pathogenic roles of cytokines in

228

http://surgerybook.net/

inflammatory bowel diseases. J Investig Med 1996;44(9):516–521.

157. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240(4856):1169–1176.

158. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood 1993;81(6):1414–1423.

159. Zurawski SM, Vega F Jr, Huyghe B, et al. Receptors for interleukin-13 and interleukin-4 are

complex and share a novel component that functions in signal transduction. EMBO J

1993;12(7):2663–2670.

160. de Waal Malefyt R, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine

production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by

IFN-gamma or IL-10. J Immunol 1993;151(11):6370–6381.

161. Billiau A, Heremans H, Vermeire K, et al. Immunomodulatory properties of interferon-gamma. An

update. Ann N Y Acad Sci 1998;856:22–32.

162. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol

1997;15:749–795.

163. Lawrence DA. Transforming growth factor-beta: an overview. Kidney Int Suppl 1995;49:S19–S23.

164. Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw

1996;7(3):363–374.

165. Wahl SM. Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte

chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987;84(16):5788–5792.

166. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp

Med 1994;180(1):83–93.

167. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever

and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med

1991;325(3):164–170.

168. Metcalf D, Nicola NA. Proliferative effects of purified granulocyte colony-stimulating factor (GCSF) on normal mouse hemopoietic cells. J Cell Physiol 1983;116(2):198–206.

169. Cooper NR. Biology of the complement system. In: Gallin JI, Snyderman R, eds. Inflammation: Basic

Principles and Clinical Correlates. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.

170. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today

1991;12(9):322–326.

171. Roitt I, Brostoff J, Male D, eds. Complement. In: Roitt I, Brostoff J, Male D, eds. Immunobiology.

3rd ed. St. Louis, MO: Mosby; 1993.

172. Weiser MR, Williams JP, Moore FD Jr, et al. Reperfusion injury of ischemic skeletal muscle is

mediated by natural antibody and complement. J Exp Med 1996;183(5):2343–2348.

173. Cooper NR. The classical complement pathway: activation and regulation of the first complement

component. Adv Immunol 1985;37:151–216.

174. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding

protein in association with a novel C1s-like serine protease. J Exp Med 1992;176(6):1497–1502.

175. Sim RB, Malhotra R. Interactions of carbohydrates and lectins with complement. Biochem Soc Trans

1994;22(1):106–111.

176. Muller-Eberhard HJ. The membrane attack complex of complement. Annu Rev Immunol

1986;4:503–528.

177. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2.

Mechanisms of catalysis and inhibition. J Biol Chem 1999;274(33):22903–22906.

178. Seeds MC, Bass DA. Regulation and metabolism of arachidonic acid. Clin Rev Allergy Immunol

1999;17(1–2):5–26.

179. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1

and -2. J Biol Chem 1996;271(52):33157–33160.

180. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science

2001;294(5548):1871–1875.

181. Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med

2000;28(4 suppl):N27–N36.

182. Gerritsen ME. Physiological and pathophysiological roles of eicosanoids in the microcirculation.

Cardiovasc Res 1996;32(4):720–732.

229

http://surgerybook.net/

183. Serhan CN. Inflammation. Signalling the fat controller. Nature 1996;384(6604):23–24.

184. Leff JA. Leukotriene modifiers as novel therapeutics in asthma. Clin Exp Allergy 1998;28(suppl

5):147–153; discussion 171–173.

185. McMahon B, Godson C. Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol

2004;286(2):F189–F201.

186. Marcus AJ. Transcellular metabolism of eicosanoids. Prog Hemost Thromb 1986;8:127–142.

187. De Caterina R, Sicari R, Giannessi D, et al. Macrophage-specific eicosanoid synthesis inhibition and

lipocortin-1 induction by glucocorticoids. J Appl Physiol 1993;75(6):2368–2375.

188. Snyder F, Fitzgerald V, Blank ML. Biosynthesis of platelet-activating factor and enzyme inhibitors.

Adv Exp Med Biol 1996;416:5–10.

189. Snyder F. Metabolic processing of PAF. Clin Rev Allergy 1994;12(4):309–327.

190. Noguchi K, Matsuzaki T, Shiroma N, et al. Involvement of nitric oxide and eicosanoids in plateletactivating factor-induced haemodynamic and haematological effects in dogs. Br J Pharmacol

1996;118(4):941–950.

191. Blais C Jr, Marceau F, Rouleau JL, et al. The kallikrein-kininogen-kinin system: lessons from the

quantification of endogenous kinins. Peptides 2000;21(12):1903–1940.

192. Erdos EG. Kinins, the long march–a personal view. Cardiovasc Res 2002;54(3):485–491.

193. Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther

1992;56(2):131–190.

194. Schreiber AD. Plasma inhibitors of the Hageman factor dependent pathways. Semin Thromb Hemost

1976;3(1):32–51.

195. Volpe AR. Giardina B, Preziosi P, et al. Biosynthesis of endothelium-derived nitric oxide by

bradykinin as endogenous precursor. Immunopharmacology 1996;33(1–3):287–290.

196. Dell’Italia LJ, Oparil S. Bradykinin in the heart: friend or foe? Circulation 1999;100(23):2305–2307.

197. Tschope C. Gohlke P, Zhu YZ, et al. Antihypertensive and cardioprotective effects after angiotensinconverting enzyme inhibition: role of kinins. J Card Fail 1997;3(2):133–148.

198. Chikanza IC, Grossman AB. Neuroendocrine immune responses to inflammation: the concept of the

neuroendocrine immune loop. Baillieres Clin Rheumatol 1996;10(2):199–225.

199. Whicker JT, Evans SW. A role for neuropeptides in inflammation. In: Whicker JT, Evans SW, eds.

Biochemistry of Inflammation. Boston, MA: Kluwer Academic; 1992.

200. Delgado M, Munoz-Elias EJ, Gomariz RP, et al. Vasoactive intestinal peptide and pituitary

adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro

and in vivo studies. J Immunol 1999;162(3):1707–1716.

201. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of

endothelium-derived relaxing factor. Nature 1987;327(6122):524–526.

202. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology.

Pharmacol Rev 1991;43(2):109–142.

203. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition.

Biochem J 2001;357(Pt 3):593–615.

204. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev

1998;17(1):7–23.

205. De Vera ME, Taylor BS, Wang Q, et al. Dexamethasone suppresses iNOS gene expression by

upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol 1997;273(6 Pt 1):G1290–

G1296.

206. Kleinert H, Euchenhofer C, Ihrig-Biedert I, et al. Glucocorticoids inhibit the induction of nitric oxide

synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factorkappa B. Mol Pharmacol 1996;49(1):15–21.

207. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1999;1411(2–3):437–455.

208. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated

by nitric oxide. Science 1992;257(5068):387–389.

209. Goodwin DC, Landino LM, Marnett LJ. Effects of nitric oxide and nitric oxide-derived species on

prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J 1999;13(10):1121–

1136.

230